semaglutide ban Critics debate banning GLP-1 weight-loss medications in sports for their potential as performance enhancers. link in bio 🔗 What possible compounded semaglutide ban

Athletes and active individuals often seek ways to reduce downtime from injury

In a trial of patients with T2DM and a BMI of 27 kg/m2 or greater being treated with semaglutide injection for weight loss, clinically significant hypoglycemia (plasma glucose less than 54 mg/dL) was reported in 6.2% of semaglutide-treated patients versus 2.5% of placebo-treated patients

The study measured changes in receptor expression, movement, and signaling, but it did not provide a direct peptide-to-receptor binding measurement

In addition to significant weight loss, Wegovy is the only GLP-1 for adults with obesity that is proven to reduce the risk of events such as stroke, heart attack, or cardiovascular death in those who also have known heart disease, said Jamey Millar, the executive vice president of Novo Nordisks US operations